Chatham Therapeutics

Baxter to acquire Chatham Therapeutics

Thursday, April 3, 2014

Baxter International, a global, diversified healthcare company, has agreed to acquire all of Chatham Therapeutics’ outstanding membership interests. Chatham is a privately held clinical development-stage biotechnology company. As a result, Baxter will acquire Chatham’s developmental gene therapy programs directed toward the development and commercialization of treatments for hemophilia.

[Read More]